 |
 |
 |
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
|
FOR IMMEDIATE RELEASE |
Media
Inquiries: |
The U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) now has a permanent leader in place following an announcement today by Commissioner Lester M. Crawford. Steven Galson MD, MPH, a Rear Admiral in the commissioned corps of the U.S. Public Health Service (PHS) will lead the more than 2200 employees of CDER who work to evaluate and approve prescription and over-the-counter drugs for their safety and efficacy. Dr. Galson's charge includes overseeing the Center's broad national and international programs in pharmaceutical regulation.
"Dr. Galson's scientific and management experience will benefit all Americans as the FDA continues to advance and protect public health," said Commissioner Crawford. "Under Steven's leadership, CDER has formed the new Drug Safety Oversight Board announced by Secretary Leavitt, created a new office to strengthen the Center's review of drugs to treat cancer and approved more than ten generic drugs under the President's Emergency Plan for AIDS Relief."
Dr. Galson joined FDA in April 2001 as the Deputy Director of CDER and most recently served in the role of the Acting Center Director. Prior to his arrival at FDA, RADM Galson was the Director of the Office of Science Coordination and Policy, Office of Prevention, Pesticides and Toxic Substances, at the Environmental Protection Agency. RADM Galson is the recipient of numerous PHS awards, most recently the Outstanding Service Medal for his leadership and management of CDER while serving as Acting Center Director from November 2001 to February 2002. RADM Galson holds a B.S. from Stony Brook University , an M.D. from Mt. Sinai School of Medicine and a MPH from the Harvard School of Public Health. He is Board Certified in Preventive Medicine & Public Health and Occupational Medicine.
####
RSS Feed for FDA News Releases [what's this?]
Get
free weekly updates about FDA press releases, recalls, speeches, testimony
and more.